Abstract:Mutant isocitrate dehydrogenase 1 (mIDH1) is a common driving factor in acute myeloid leukemia (AML), with the R132 mutation accounting for a high proportion. The U.S. Food and Drug Administration (FDA) approved Ivosidenib, a molecular entity that targets IDH1 with R132 mutations, as a promising therapeutic option for AML with mIDH1 in 2018. It was of concern that the occurrence of disease resistance or recurrence, attributed to the IDH1 R132C/S280F second site mutation, was observed in certain patients treated with Ivosidenib within the same year. Furthermore, it should be noted that most mIDH1 inhibitors demonstrated limited efficacy against mutations at this specific site. Therefore, there is an urgent need to investigate novel inhibitors targeting mIDH1 for combating resistance caused by IDH1 R132C/S280F mutations in AML. This study aimed to identify novel mIDH1 R132C/S280F inhibitors through an integrated strategy of combining virtual screening and dynamics simulations. First, 2000 hits were obtained through structure-based virtual screening of the COCONUT database, and hits with better scores than −10.67 kcal/mol were obtained through molecular docking. A total of 12 potential small molecule inhibitors were identified through pharmacophore modeling screening and Prime MM-GBSA. Dynamics simulations were used to study the binding modes between the positive drug and the first three hits and IDH1 carrying the R132C/S280F mutation. RMSD showed that the four dynamics simulation systems remained stable, and RMSF and Rg showed that the screened molecules have similar local flexibility and tightness to the positive drug. Finally, the lowest energy conformation, hydrogen bond analysis, and free energy decomposition results indicate that in the entire system the key residues LEU120, TRP124, TRP267, and VAL281 mainly contribute van der Waals forces to the interaction, while the key residues VAL276 and CYS379 mainly contribute electrostatic forces.

Identification of small-molecule inhibitors of human MUS81-EME1/2 by FRET-based high-throughput screening

Fragment-Based Discovery of Novel MUS81 Inhibitors

A high-throughput screen of pharmacologically active compounds for inhibitors of UHRF1 reveals epigenetic activity of anthracycline derivative chemotherapeutic drugs.

Inhibitor development of MTH1 via high-throughput screening with fragment based library and MTH1 substrate binding cavity

Discovery of UMI-77 as a novel Ku70/80 inhibitor sensitizing cancer cells to DNA damaging agents in vitro and in vivo

Discovery of novel non-nucleoside inhibitors with high potency and selectivity for DNA methyltransferase 3A

Screening inhibitors for blocking UHRF1-methylated DNA interaction with capillary electrophoresis

A Small Molecule Inhibitor of the UBE2F-CRL5 Axis Induces Apoptosis and Radiosensitization in Lung Cancer

Inhibition of MUS81 Improves the Chemical Sensitivity of Olaparib by Regulating MCM2 in Epithelial Ovarian Cancer.

Identification of mIDH1 R132C/S280F Inhibitors from Natural Products by Integrated Molecular Docking, Pharmacophore Modeling and Molecular Dynamics Simulations

Rapid identification of dual p53-MDM2/MDMX interaction inhibitors through virtual screening and hit-based substructure search

Human MUS81: A Fence-Sitter in Cancer

Supercomputer-Based Virtual Screening for Deoxyribonucleic Acid Methyltransferase 1 Inhibitors as Novel Anticancer Agents

Acute Mus81 Depletion Leads to Replication Fork Slowing and A Constitutive Dna Damage Response

Design, synthesis and biological evaluation of 4-(indolin-1-yl)-6-substituted-pyrido[3,2- d ]pyrimidine derivatives as Mnk1/2 inhibitors

MUS81 Inhibition Increases the Sensitivity to Therapy Effect in Epithelial Ovarian Cancer Via Regulating CyclinB Pathway

Complementary non-radioactive assays for investigation of human flap endonuclease 1 activity

Identification of drug-like molecules targeting the ATPase activity of dynamin-like EHD4

Identification of Novel Disruptor of Telomeric Silencing 1-like (DOT1L) Inhibitors through Structure-Based Virtual Screening and Biological Assays.

Fragment-based discovery of new potential DNMT1 inhibitors integrating multiple pharmacophore modeling, 3D-QSAR, virtual screening, molecular docking, ADME, and molecular dynamics simulation approaches

The Facile and Visualizable Identification of Broad-Spectrum Inhibitors of MDM2/p53 Using Co-Expressed Protein Complexes